Controversions in perimenopause and postmenopause
Authors:
MUDr. Peter Koliba, CSc.
Authors‘ workplace:
přednosta Porodnicko-gynekologické kliniky FNsP Ostrava
Published in:
Prakt Gyn 2005; 9(2): 24-26
Overview
The author gives a review of basic controversions and the development of views of HRT administration to the patients in climacterium period. First of all he deals with the influence of HRT on the endometrium cancer, breast cancer, ischemic heart disease, thromboembolic disease, vegetative climacteric syndrome, central neural system, osteoporosis and collorectal cancer. He also outlines the issue of phytoestrogens and the perspective of their use.
Key words:
HRT – climacterium – menopause – perimenopause – postmenopause
Sources
1. ACOG committee opinion: Hormone replacement therapy in women with previously treated breast cancer. Int J Gynec Obstet 2000; 69: 67-71.
2. Brincat MP. Hormone replacement therapy and the skin: beneficial effects: the case in favor of it.Acta Obstet. Gynec Scand 2000; 79: 244-249.
3. Čepický P et al. Doporučení k hormonální terapii a substituci perimenopauzy a postmenopauzy. Moder Gynekol 2003; 10(Suppl 4) 707–711.
4. Čepický P et al. Kulatý stůl o HRT, Praha, 7. května 2004.
5. Čepický P, Líbalová Z. Klíč k racionální diagnostice a terapii poruch menopauzy. Moder Gynekol 2003; 10(Suppl 4) 720–722.
6. Donát J. Hormonální substituční terapie. Hradec Králové: DoMeNa 1999.
7. Donát J. Perimenopauza, menopauzální přechod v klinické praxi. Hradec Králové: DoMeNa 2001.
8. Fletcher SW, Colditz GA. Failure of Estrogen Plus Progestin Therapy for Prevention. JAMA 2002; 288: 366-368.
9. Glass M, Rebar R. Hormone replacement for the new millennium. Obstet Gynec Clin N Amer 2000; 27(3): 611-623.
10. Greiser ME et al. WHI Breast cancer results and public health concern.
http:// bmj.com/cgi/eletters/325/7356/113. 7/2002.
11. Humphrey LL et al. Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease. Ann Intern Med 2002; 137: 273-284.
12. Jeníček J. Změna nízkodávkované hormonální antikoncepce na hormonální substituční léčbu v perimenopauze a menopauze. Moder Gynekol 2003; 10(Suppl 4).
13. Jeníček J. Hormonální substituční terapie a klimakterium. Praha: Grada 2001.
14. Koblihová I. Neodkladná informace lékařům ve věci hormonální substituční terapie. SÚKL, dopis lékařům, 3.12. 2003.
15. Koliba P et al. Přehled hormonální substituční terapie. Prakt Gyn 2001; 4: 31-37.
16. Kořenek A. Hormonální kontracepce v premenopauze – úvod. Moder Gynekol 2003; 10(Suppl 4).
17. Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427.
18. Nelson HD et al. Postmenopausal Hormone Replacement Therapy: Scientific Review. JAMA 2002; 288: 872-881.
19. Neves-e-Castro M et al. Results from WHI and HERS II – Implications for women and the prescriber of HRT. Maturitas 2002; 42: 255-258.
20. Polo-Kantola P, Erkkola R. Alzheimer's disease and estrogen replacement therapy - where are we now? Acta obstet gynec scand 2001; 80: 679-682.
21. Ravnikar V et al. Perspektivy HRT po zveřejnění výsledků studie WHI – názory
expertů. Gynekologie po promoci 2003; 2.
22. Rozenbaum H. 100 years of Hormone Replacement Therapy. In: IV. European Congress on Menopause. Vienna (Austria) 1998: 13-26 (sborník).
23. Speroff L, Clarkson T. Je tibolon reálnou alternativou hormonální substituční terapie? Gynekologie po promoci 2003; 3.
24. Stevenson JC. USA Women's Health Initiative Oestrogen plus Progestogen HRT terminated early.www.the-bms.org/hrt_info.htm,7/2002
25. Stevenson JC, Whitehead MI. Hormone replacement therapy. Findings of women´s health initiative trial need not alarm users. BMJ 2002; 325: 113-114.
26. Svobodová K. Podvod na ženách. Týden 2002; 36: 30-34.
27. What prompted FDA to request the changes in the physician prescribing information and patient information leaflet for all estrogen and estrogen with progestin drug products? www.fda.gov/cder/drug/infopage/estrogens_progestins/Q&A.htm - 04 -19-2004
28. Writing Group for the Women's Health Initiative Investigators: Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women.Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-333.
29. Vrublová Y. Sexualita stárnoucích lidí. In: VIII. Gerontologické dny. Ostrava 13. října 2004: 8-10 (sborník).
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Practical Gynecology
2005 Issue 2
Most read in this issue
- Chlamydias in ejaculate; the influence on the quality and morphology of sperms
- Developmental defects in reproduction losses in the 1st trimester of pregnancy
- Minimal stimulation in the IVF/ICSI+ET programme
- Controversions in perimenopause and postmenopause